Table 4.
Nanochitosan (composite) | Target cell(s) | Mechanism of action | Test | Outcome | Year | Ref. |
---|---|---|---|---|---|---|
Nano chitosan | Breast cancer mice model 4 | Interference to RNA and immunoenhancement | In vivo | Inhibition of angiogenesis and proliferation | 2010 2015 |
[17] [211] |
Human gastric cancer cells | Sustained release manner | In vitro | Inhibition of cells proliferation | 2010 2005 |
[17] [213] |
|
Ovarian cancer cells | Binding of αvβ3 integrin with tumor cell receptors | In vivo | Inhibition of tumor growth | 2010 | [216] | |
HCC cells | Decrease in mitochondrial membrane potential, and fragmentation of DNA, suppression of VEGFR2 gene expression | In vitro | Cell death and inhibition of angiogenesis | 2010 2007 |
[17] [95] |
|
| ||||||
Paclitaxel-glycol chitosan nano composite | MCF-7 | sustained release of paclitaxel by EPR effect | In vitro | Tumor growth inhibition | 2006 | [214] |
| ||||||
Chitosan-curcumin nano formulation | Solid tumor | Sustained release manner, DNA damage, cell cycle blockage and elevation of ROS levels | In vitro | Inhibition of tumor growth | 2018 | [219] |
| ||||||
Chitosan folate hesperetin nanoparticles | HCT15 cells | Passive targeting through the leaky vasculature of tumor environment | In vivo | Cellular apoptosis | 2018 | [220] |
| ||||||
Peptide-labeled chitosan nanoparticle | Solid tumors | Tumor targeted delivery for short interfering RNA (siRNA) | In vivo | Inhibition of tumor growth | 2010 | [216] |